Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer

S. Tsujitani, Y. Kakeji, H. Orita, A. Watanabe, S. Kohnoe, H. Baba, H. Anai, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To determine the group of patients for whom a biological response modifier is useful, the efficacy of postoperative adjuvant immunotherapy was investigated with regard to infiltration of dendritic cells (DC) in patients with advanced gastric cancer who underwent absolute curative resection. The infiltration of DC was classified into marked and slight. The chemotherapy group was prescribed mitomycin C and tegafur, while for the immunochemotherapy group a biological response modifier, PSK, was also prescribed in survival between the chemotherapy and immunochemotherapy groups. In patients with slight infiltration, however, the 5 - year survival rates were 0% in the chemotherapy and 15% in the immunochemotherapy group. Patients given PSK survived longer than those given chemotherapy only (P<0.05). Therefore, adjuvant immunotherapy may be considered for patients with advanced gastric cancer with slight infiltration of DC.

Original languageEnglish
Pages (from-to)645-648
Number of pages4
JournalAnticancer research
Volume12
Issue number3
Publication statusPublished - Jan 1 1992

Fingerprint

Dendritic Cells
Stomach Neoplasms
Drug Therapy
Immunologic Factors
Immunotherapy
Tegafur
Mitomycin
Survival Rate
Survival
krestin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tsujitani, S., Kakeji, Y., Orita, H., Watanabe, A., Kohnoe, S., Baba, H., ... Sugimachi, K. (1992). Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer research, 12(3), 645-648.

Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. / Tsujitani, S.; Kakeji, Y.; Orita, H.; Watanabe, A.; Kohnoe, S.; Baba, H.; Anai, H.; Maehara, Y.; Sugimachi, K.

In: Anticancer research, Vol. 12, No. 3, 01.01.1992, p. 645-648.

Research output: Contribution to journalArticle

Tsujitani, S, Kakeji, Y, Orita, H, Watanabe, A, Kohnoe, S, Baba, H, Anai, H, Maehara, Y & Sugimachi, K 1992, 'Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer', Anticancer research, vol. 12, no. 3, pp. 645-648.
Tsujitani S, Kakeji Y, Orita H, Watanabe A, Kohnoe S, Baba H et al. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer research. 1992 Jan 1;12(3):645-648.
Tsujitani, S. ; Kakeji, Y. ; Orita, H. ; Watanabe, A. ; Kohnoe, S. ; Baba, H. ; Anai, H. ; Maehara, Y. ; Sugimachi, K. / Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. In: Anticancer research. 1992 ; Vol. 12, No. 3. pp. 645-648.
@article{0a5fc0c755964398b2e07146efe75340,
title = "Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer",
abstract = "To determine the group of patients for whom a biological response modifier is useful, the efficacy of postoperative adjuvant immunotherapy was investigated with regard to infiltration of dendritic cells (DC) in patients with advanced gastric cancer who underwent absolute curative resection. The infiltration of DC was classified into marked and slight. The chemotherapy group was prescribed mitomycin C and tegafur, while for the immunochemotherapy group a biological response modifier, PSK, was also prescribed in survival between the chemotherapy and immunochemotherapy groups. In patients with slight infiltration, however, the 5 - year survival rates were 0{\%} in the chemotherapy and 15{\%} in the immunochemotherapy group. Patients given PSK survived longer than those given chemotherapy only (P<0.05). Therefore, adjuvant immunotherapy may be considered for patients with advanced gastric cancer with slight infiltration of DC.",
author = "S. Tsujitani and Y. Kakeji and H. Orita and A. Watanabe and S. Kohnoe and H. Baba and H. Anai and Y. Maehara and K. Sugimachi",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "645--648",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer

AU - Tsujitani, S.

AU - Kakeji, Y.

AU - Orita, H.

AU - Watanabe, A.

AU - Kohnoe, S.

AU - Baba, H.

AU - Anai, H.

AU - Maehara, Y.

AU - Sugimachi, K.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - To determine the group of patients for whom a biological response modifier is useful, the efficacy of postoperative adjuvant immunotherapy was investigated with regard to infiltration of dendritic cells (DC) in patients with advanced gastric cancer who underwent absolute curative resection. The infiltration of DC was classified into marked and slight. The chemotherapy group was prescribed mitomycin C and tegafur, while for the immunochemotherapy group a biological response modifier, PSK, was also prescribed in survival between the chemotherapy and immunochemotherapy groups. In patients with slight infiltration, however, the 5 - year survival rates were 0% in the chemotherapy and 15% in the immunochemotherapy group. Patients given PSK survived longer than those given chemotherapy only (P<0.05). Therefore, adjuvant immunotherapy may be considered for patients with advanced gastric cancer with slight infiltration of DC.

AB - To determine the group of patients for whom a biological response modifier is useful, the efficacy of postoperative adjuvant immunotherapy was investigated with regard to infiltration of dendritic cells (DC) in patients with advanced gastric cancer who underwent absolute curative resection. The infiltration of DC was classified into marked and slight. The chemotherapy group was prescribed mitomycin C and tegafur, while for the immunochemotherapy group a biological response modifier, PSK, was also prescribed in survival between the chemotherapy and immunochemotherapy groups. In patients with slight infiltration, however, the 5 - year survival rates were 0% in the chemotherapy and 15% in the immunochemotherapy group. Patients given PSK survived longer than those given chemotherapy only (P<0.05). Therefore, adjuvant immunotherapy may be considered for patients with advanced gastric cancer with slight infiltration of DC.

UR - http://www.scopus.com/inward/record.url?scp=0026665191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026665191&partnerID=8YFLogxK

M3 - Article

C2 - 1622120

AN - SCOPUS:0026665191

VL - 12

SP - 645

EP - 648

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -